Stockscreener 앱 받기
37.50
0.73%
0.27
Springworks Therapeutics Inc 주식(SWTX)의 최신 뉴스
Vanguard Group Inc. Expands Holdings in SpringWorks Therapeutics Inc. - GuruFocus.com
SpringWorks Therapeutics to Report Fourth Quarter and Full - GlobeNewswire
SpringWorks Therapeutics Plans Major Q4 Update: Key Business Milestones & 2024 Performance Review - StockTitan
Learn to Evaluate (SWTX) using the Charts - Stock Traders Daily
Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives $70.00 Average PT from Analysts - Defense World
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 4.8%Here's What Happened - MarketBeat
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma - Marketscreener.com
AMI Asset Management Corp Takes $1.44 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Analysts Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Target Price at $70.00 - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Down 6.4%Time to Sell? - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 4.3%Time to Buy? - MarketBeat
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
SpringWorks Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - MSN
Research Analysts Set Expectations for SWTX FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for SWTX FY2027 Earnings - Defense World
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap DownHere's What Happened - MarketBeat
Wedbush Research Analysts Reduce Earnings Estimates for SWTX - MarketBeat
JPMorgan Chase & Co. Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics’ SWOT analysis: biotech stock shows promise amid challenges - Investing.com Nigeria
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Items Tagged with 'RPT-04402' - BioWorld Online
Items Tagged with 'SW-3431' - BioWorld Online
Springworks licenses molecular glue targeting PP2A from Rappta - BioWorld Online
Why Springworks Therapeutics Stock is Tumbling - TipRanks
SpringWorks Therapeutics (NASDAQ:SWTX) Given Outperform Rating at Wedbush - Defense World
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
Wedbush Reiterates "Outperform" Rating for SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
SpringWorks to Develop Rappta’s First-in-Class Cancer Drug - Contract Pharma
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
SpringWorks Therapeutics Reports Strong 2024 Financial Results - TipRanks
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
SpringWorks Therapeutics Reports Preliminary Fourth Quarter - GlobeNewswire
SpringWorks Therapeutics Hits $172M Revenue in 2024 as OGSIVEO Launch Accelerates Growth - StockTitan
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate (SWTX) - Seeking Alpha
SpringWorks Therapeutics jumps amid takeover speculation - MSN
Guggenheim Lowers SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $78.00 - Defense World
SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim - Yahoo Finance
Guggenheim Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $78.00 - MarketBeat
3.95%
2.39%
자본화:
|
볼륨(24시간):